Global Oncology Companion Diagnostics Market - 2025-2033

July 2026 | 63 pages | ID: G97967B83DBCEN
DataM Intelligence

Abstracts

Global Oncology Companion Diagnostics Market reached US$ 5.98 billion in 2026 and is expected to reach US$ 13.09 billion by 2035, growing with a CAGR of 9.10% during the forecast period 2026-2035.

The Global Oncology Companion Diagnostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Global Oncology Companion Diagnostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Product Type

• Instruments*
• Consumables
• Software

By Technology

• Polymerase Chain Reaction (PCR)*
• Next?Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH/FISH)
• Liquid Biopsy
• Others

By Application

• Non?Small Cell Lung Cancer (NSCLC)*
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

By End-User

• Hospitals*
• Diagnostic Laboratories
• Academic and Research Institutions
• Others

Regional Analysis for Global Oncology Companion Diagnostics Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Global Oncology Companion Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising Prevalence of Cancer
    3.1.1.2. Precision Oncology & Rise of Targeted Therapies
  3.1.2. Restraints
    3.1.2.1. Limited Biomarker Access & Heterogeneity
    3.1.2.2. Complex Regulatory Pathways for Co-Approval
  3.1.3. Opportunity
    3.1.3.1. Expansion into Emerging Markets
    3.1.3.2. Rise of Liquid Biopsy-Based Companion Diagnostics
  3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established Leaders with the Largest Marketing Brand
  4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics

5. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY PRODUCT TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
5.4. Software

6. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  6.1.2. Market Attractiveness Index, By Technology
6.2. Polymerase Chain Reaction (PCR)*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Next?Generation Sequencing (NGS)
6.4. Immunohistochemistry (IHC)
6.5. In Situ Hybridization (ISH/FISH)
6.6. Liquid Biopsy
6.7. Others

7. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY APPLICATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  7.1.2. Market Attractiveness Index, By Application
7.2. Non?Small Cell Lung Cancer (NSCLC)*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Breast Cancer
7.4. Prostate Cancer
7.5. Colorectal Cancer
7.6. Others

8. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY END-USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Laboratories
8.4. Academic and Research Institutions
8.5. Others

9. ONCOLOGY COMPANION DIAGNOSTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10. INTRODUCTION

10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.1. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.7.1. U.S.
    10.2.7.2. Canada
    10.2.7.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.7.1. Germany
    10.3.7.2. UK
    10.3.7.3. France
    10.3.7.4. Spain
    10.3.7.5. Italy
    10.3.7.6. Rest of Europe
10.4. Asia-Pacific
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.7.1. China
    10.4.7.2. India
    10.4.7.3. Japan
    10.4.7.4. South Korea
    10.4.7.5. Rest of Asia-Pacific
10.5. South America
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.7.1. Brazil
    10.5.7.2. Argentina
    10.5.7.3. Rest of South America
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking

12. COMPANY PROFILES

12.1. F. Hoffmann-La Roche Ltd*
  12.1.1. Company Overview
  12.1.2. Product Portfolio
    12.1.2.1. Product Description
    12.1.2.2. Product Key Performance Indicators (KPIs)
  12.1.3. Financial Overview
    12.1.3.1. Company Revenue
    12.1.3.2. Geographical Revenue Shares
    12.1.3.3. Revenue Forecasts
  12.1.4. Key Developments
    12.1.4.1. Mergers & Acquisitions
    12.1.4.2. Key Product Development Activities
    12.1.4.3. Regulatory Approvals, etc.
    12.1.4.4. SWOT Analysis
12.2. Agilent Technologies, Inc.
12.3. Illumina, Inc.
12.4. QIAGEN
12.5. Thermo Fisher Scientific Inc.
12.6. Myriad Genetics, Inc.
12.7. Guardant Health
12.8. Labcorp
12.9. Quest Diagnostics
12.10. Invivoscribe, Inc. (LIST NOT EXHAUSTIVE)
ASSUMPTIONS AND RESEARCH METHODOLOGY

1. DATA COLLECTION METHODS

2. DATA TRIANGULATION

3. FORECASTING TECHNIQUES

4. DATA VERIFICATION AND VALIDATION

5. APPENDIX

5.1. About Us and Services
5.2. Contact Us